Human medicines European public assessment report (EPAR): Ayvakyt, avapritinib, Date of authorisation: 24/09/2020, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Nurzigma, pridopidine, Status: Application withdrawn

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 51, Status: Authorised

Human medicines European public assessment report (EPAR): Harvoni, ledispavir,sofosbuvir, Date of authorisation: 17/11/2014, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Sovaldi, sofosbuvir, Date of authorisation: 16/01/2014, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Rimmyrah, ranibizumab, Date of authorisation: 05/01/2024, Revision: 4, Status: Authorised

Fifteenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines, Online, European Medicines Agency, Amsterdam, the Netherlands, from 28 November 2025, 09:00 (CET) to 28 November 2025, 13:00 (CET)

PSUSA/00002437/202503

PSUSA/00000811/202503

Financial management and budgetary reporting